Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pulmocide Ltd
Finance Watch: $1.32bn In New Biopharma VC Financings As Year-End Approaches
Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.
Pulmocide Grows Cash Pile For Promising Antifungal
The UK firm has announced an extension of its series C financing which means it has raised just shy of $150m in the last 18 months to fund clinical development, manufacturing scale-up and preparations for the potential commercialization of opelconazole.
Osel Sees Immunotherapy-Like Trajectory For Oncology Microbiome Candidate
Depending on financing, the company could start a Phase III trial of CBM588 as early as this year, but it’s looking to develop the microbiome therapeutic for a potentially broad array of cancers.
Finance Watch: Two New VC Funds Raise $955m To Back Life Science Companies
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
- Drug Delivery
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.